Minoryx Therapeutics

Minoryx Therapeutics is a clinical-stage biotech company focused on the discovery and development of treatments for severe, orphan diseases of the central nervous system. The company's lead asset, leriglitazone, is a selective PPAR gamma agonist currently in clinical development for X-linked Adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome. Their target market includes pediatric and adult patients suffering from neurodegenerative conditions with high unmet medical needs.